Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- Scope of the problem
- Dengue transmission in 128 countries
- Dengue virus global distribution
- 2010 disease burden
- Increasing dengue burden
- Why is dengue such a big problem today?
- The crash in mosquito control
- Aedes aegypti in the Americas
- Dengue fever (DF) & hemorrhagic fever (DHF)
- Are four viruses needed in a dengue vaccine?
- Second infection sequences leading to DHF
- Infection sequences with no data
- Third infections that do and don't result in DHF
- A vaccine against each of the four dengue viruses
- Vaccine approaches: Live-attenuated viruses
- Mahidol Univ./Aventis
- Attenuation by serial passage in tissue cultures
- Problems with DENV 3 GMK 30/FRhL 3
- Vaccine development abandoned
- GSK
- Tetravalent dengue vaccine co-development
- WRAIR/GSK tetravalent vaccine
- Re-derived vaccine: Phase l/ll 2010-14
- Vaccine approaches: Genetically altered viruses
- NIH
- Molecular attenuation / D4 chimera
- NIH vaccine, progress to date: monkey trials
- NIH vaccine, development strategy in humans
- NIH vaccine, progress to date: human trials
- NIH vaccine, progress to date: tetravalent vaccine
- Takeda
- Takeda/Inviragen/CDC
- Takeda vaccine: progress to date
- Sanofipasteur
- ChimeriVax technology: YF 17D live vector
- ChimeriVax vaccine, progress: monkey trials
- ChimeriVax vaccine: phase I/II human trials
- ChimeriVax vaccine, phase IIb/III clinical trials
- ChimeriVax vaccine: prevention of hospitalization
- ChimeriVax vaccine: prevention of plasma leakage
- ChimeriVax vaccine, serotype specific infections
- ChimeriVax vaccine: protection summary
- Vaccine approaches: DNA, inactivated viruses
- DNA vaccines
- Benefits of inactivated vaccines
- Purified inactivated vaccine (PIV) (1)
- Purified inactivated vaccine (PIV) (2)
- Hawaii Biotech/Merck dengue vaccine
- Merck vaccine, progress: monkey trials
- Merck vaccine, progress: phase I human trial
- Summary (1)
- Summary (2)
Topics Covered
- Scope of the dengue problem
- Assessing the need for a tetravalent vaccine
- In-depth look at current vaccines and their development status
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Halstead, S. (2015, May 28). Dengue vaccine development: l. status [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 5, 2024, from https://doi.org/10.69645/OFMC6948.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Scott Halstead has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:00
This is Scott Halstead, and I'm going to be giving
two lectures on current dengue vaccine development.
I have been an officer of the
Dengue Vaccine Initiative located
at the International
Vaccine Institute
in Seoul, Korea for
more than 10 years.
The first lecture describes the
current status of dengue vaccine
development, and the second
will describe the uses
and deployment of these vaccines.
0:26
So the lecture will
cover three topics.
One is the scope of the
problem of dengue in the world.
And do we need a
tetravalent dengue vaccine?
And then we'll describe
each of the current vaccines
that are in development, and
their development status.
0:45
So scope of the problem.
0:49
As you can see from this
recent global map of the Earth,
there is a belt in
the tropical regions
around the entire globe were
dengue viruses are transmitted.
This amounts to transmission
in 128 different countries.
And this slide shows the
intensity of transmission.
The blue dots are actually reports
either from individual countries
or published in the literature.
So those are indications
of current activity.
But the colors on the
chart, intense red meaning
endemic transmission to
green meaning no transmission
give you a quick idea.
You can see that most of
the temperate countries
do not currently have
dengue transmission,
either in northern or
southern hemisphere.
1:35
Now here's the bad
news, which is A, there
are four different dengue viruses.
They've all evolved from a
common ancestor to be 30% to 40%
genetically different.
And although they perhaps all
originated in Southeast Asia,
they have spread around the world.
And now in each of the
endemic areas of the world,
in the American, African, and Asian
tropics, all of the four viruses
are in circulation.